Eculizumab was studied unsuccessfully in the past in patients with membranous nephropathy, a disease in which the alternate complement pathway is not over-activated. Despite the negative findings of this study, experience with the medication was gained at Columbia University Medical Center; in fact, we were one of the largest recruiting sites for this placebo controlled randomized blinded trial.